Literature DB >> 1509293

Advances in the diagnosis and management of myeloma.

P R Greipp1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1509293

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  6 in total

1.  Unfolded protein response inducers tunicamycin and dithiothreitol promote myeloma cell differentiation mediated by XBP-1.

Authors:  Hua Jiang; Jianfeng Zou; Hui Zhang; Weijun Fu; Tianmei Zeng; Hejing Huang; Fan Zhou; Jian Hou
Journal:  Clin Exp Med       Date:  2013-12-20       Impact factor: 3.984

2.  Presenting signs and symptoms in multiple myeloma: high percentages of stage III among patients without apparent myeloma-associated symptoms.

Authors:  F Ong; J Hermans; E M Noordijk; P W Wijermans; J C Kluin-Nelemans
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

3.  Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice? Application of three classification systems to a large population-based registry of paraproteinemia and multiple myeloma.

Authors:  F Ong; J Hermans; E M Noordijk; J C Kluin-Nelemans
Journal:  Ann Hematol       Date:  1995-01       Impact factor: 3.673

4.  The normal counterpart of IgD myeloma cells in germinal center displays extensively mutated IgVH gene, Cmu-Cdelta switch, and lambda light chain expression.

Authors:  C Arpin; O de Bouteiller; D Razanajaona; I Fugier-Vivier; F Brière; J Banchereau; S Lebecque; Y J Liu
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

5.  A prognostic index for multiple myeloma.

Authors:  G Grignani; P G Gobbi; R Formisano; C Pieresca; G Ucci; S Brugnatelli; A Riccardi; E Ascari
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

6.  Effects of the glucolipid synthase inhibitor, P4, on functional and phenotypic parameters of murine myeloma cells.

Authors:  L S Manning; N S Radin
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.